Navidea Biopharmaceuticals Incの利益マージン
Navidea Biopharmaceuticals Incの利益マージンは何ですか。
Navidea Biopharmaceuticals Incの利益マージンは-23,920.26%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
NYSEMKTのセクタHealth Careにおける利益マージンの企業と比べるNavidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Incは何をしますか。
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Incと類似の利益マージン
- Chimerix Incの利益マージンは-25,337.96%です。
- Digital Wine Venturesの利益マージンは-24,985.82%です。
- Nova Mineralsの利益マージンは-24,425.53%です。
- Australian Vanadiumの利益マージンは-24,133.33%です。
- Yield10 Bioscience Incの利益マージンは-24,091.67%です。
- Ardea Resourcesの利益マージンは-23,955.53%です。
- Navidea Biopharmaceuticals Incの利益マージンは-23,920.26%です。
- Lefroy Explorationの利益マージンは-23,800.00%です。
- Reata Pharmaceuticals Incの利益マージンは-23,659.05%です。
- Timber Pharmaceuticalsの利益マージンは-23,349.40%です。
- Cardinal Resourcesの利益マージンは-23,106.25%です。
- RTG Miningの利益マージンは-23,000.00%です。
- RTG Miningの利益マージンは-23,000.00%です。